Nektar Therapeutics (MEX:NKTR) Cyclically Adjusted Book per Share: MXN1,120.10 (As of Mar. 2026)


MEX:NKTR Nektar Therapeutics MEX:NKTR
47 GF Score
Price MXN1,584.15
GF Value MXN131.79
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Cyclically Adjusted Book per Share?

Nektar Therapeutics MEX:NKTR 47 Cyclically Adjusted Book per Share is MXN1,120.10 as of Mar. 2026. GuruFocus rates MEX:NKTR with a GF Score™ of 47/100 and a GF Value™ of MXN131.79. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nektar Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was MXN352.563. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN1,120.10 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Nektar Therapeutics's average Cyclically Adjusted Book Growth Rate was 3.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nektar Therapeutics was 49.10% per year. The lowest was -26.40% per year. And the median was 1.30% per year.

As of today (2026-07-03), Nektar Therapeutics's current stock price is MXN1584.15. Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN1,120.10. Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is 1.41.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 5.98.


Nektar Therapeutics  (MEX:NKTR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1584.15/1120.10
=1.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 5.98.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nektar Therapeutics Cyclically Adjusted Book per Share Related Terms


Nektar Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Cyclically Adjusted Book per Share Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,086.02 7,171.67 5,084.77 1,128.97 1,449.02

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,471.00 377.76 568.10 1,449.02 1,120.10

MEX:NKTR vs OCUL, PVLA, GENB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PB Ratio falls into.


MEX:NKTR
47GF Score
Nektar Therapeutics MEX:NKTR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=352.563/330.2130*330.2130
=352.563

Current CPI (Mar. 2026) = 330.2130.

Nektar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -79.707 241.018 -109.205
201609 -142.823 241.428 -195.346
201612 177.881 241.432 243.293
201703 81.685 243.801 110.637
201706 5.890 244.955 7.940
201709 145.964 246.819 195.282
201712 162.191 246.524 217.251
201803 97.816 249.554 129.431
201806 3,180.460 251.989 4,167.758
201809 2,902.334 252.439 3,796.515
201812 2,915.082 251.233 3,831.495
201903 2,728.097 254.202 3,543.847
201906 2,564.406 256.143 3,305.967
201909 2,507.905 256.759 3,225.370
201912 2,252.543 256.974 2,894.530
202003 2,563.552 258.115 3,279.616
202006 2,432.401 257.797 3,115.670
202009 2,162.888 260.280 2,744.021
202012 1,784.904 260.474 2,262.792
202103 1,672.731 264.877 2,085.336
202106 1,470.326 271.696 1,787.000
202109 1,339.505 274.310 1,612.489
202112 1,127.329 278.802 1,335.208
202203 974.688 287.504 1,119.479
202206 738.656 296.311 823.168
202209 661.761 296.808 736.241
202212 568.608 296.797 632.627
202303 344.134 301.836 376.488
202306 266.401 305.109 288.320
202309 218.274 307.789 234.176
202312 174.262 306.746 187.594
202403 171.772 312.332 181.606
202406 118.971 314.175 125.044
202409 78.274 315.301 81.976
202412 102.278 315.605 107.012
202503 22.653 319.799 23.391
202506 -36.596 322.561 -37.464
202509 79.420 324.800 80.744
202512 79.370 324.054 80.879
202603 352.563 330.213 352.563

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN1,120.10 mean?
Nektar Therapeutics (MEX:NKTR) has a Cyclically Adjusted Book per Share of MXN1,120.10 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Cyclically Adjusted Book per Share too high?
Nektar Therapeutics' current Cyclically Adjusted Book per Share is MXN1,120.10. Overall, Nektar Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Cyclically Adjusted Book per Share compare to OCUL and PVLA?
Nektar Therapeutics' Cyclically Adjusted Book per Share of MXN1,120.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Cyclically Adjusted Book per Share is MXN1,120.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Nektar Therapeutics (MEX:NKTR) has a current Cyclically Adjusted Book per Share of MXN1,120.10. The stock's GF Value™ is MXN131.79, compared to a current price of MXN1,584.15 — trading 1102% above its estimated fair value. The current Cyclically Adjusted Book per Share is MXN1,120.10. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Nektar Therapeutics (MEX:NKTR), the current Cyclically Adjusted Book per Share is MXN1,120.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (MEX:NKTR) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of MXN1,584.15 is trading 1102% above its estimated GF Value™ of MXN131.79.

Key valuation signals for MEX:NKTR:

  • Cyclically Adjusted Book per Share: MXN1,120.10
  • GF Value™: MXN131.79 vs. price of MXN1,584.15 (1102% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the MEX:NKTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for MEX:NKTR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,584.15
Price
MXN131.79
GF Value